Last Updated : February 27, 2025
Details
Generic Name:
nemolizumab
Project Status:
Received
Therapeutic Area:
atopic dermatitis
Manufacturer:
Galderma Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0869-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of moderate-to-severe AD in patients aged 12 years and
older whose disease is not adequately controlled with topical prescription
therapies or when those therapies are not advisable, and/or who are refractory
to or ineligible for systemic immunosuppressant therapies.
Fee Schedule:
Pending
Indications:
For the treatment of moderate-to-severe atopic dermatitis (AD) in patients
aged 12 years and older who are candidates for systemic therapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | January 15, 2025 |
|---|---|
| Call for patient/clinician input closed | March 10, 2025 |
| Submission received | February 27, 2025 |
| Submission accepted | - |
Last Updated : February 27, 2025